NZ332476A - substituted 4-(carboxybenzylsulphinyl)-2-oxo-azetidine derivatives - Google Patents
substituted 4-(carboxybenzylsulphinyl)-2-oxo-azetidine derivativesInfo
- Publication number
- NZ332476A NZ332476A NZ332476A NZ33247697A NZ332476A NZ 332476 A NZ332476 A NZ 332476A NZ 332476 A NZ332476 A NZ 332476A NZ 33247697 A NZ33247697 A NZ 33247697A NZ 332476 A NZ332476 A NZ 332476A
- Authority
- NZ
- New Zealand
- Prior art keywords
- compound
- oxoazetidin
- fluorophenyl
- alkyl
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
- C07D205/09—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9608646.7A GB9608646D0 (en) | 1996-04-26 | 1996-04-26 | Novel compounds |
GBGB9623756.5A GB9623756D0 (en) | 1996-11-15 | 1996-11-15 | Novel compounds |
GBGB9625121.0A GB9625121D0 (en) | 1996-12-03 | 1996-12-03 | Novel compounds |
PCT/EP1997/001898 WO1997041098A1 (en) | 1996-04-26 | 1997-04-15 | Azetidinone derivatives for the treatment of atherosclerosis |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ332476A true NZ332476A (en) | 2000-06-23 |
Family
ID=27268259
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ332476A NZ332476A (en) | 1996-04-26 | 1997-04-15 | substituted 4-(carboxybenzylsulphinyl)-2-oxo-azetidine derivatives |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP0915843A1 (hu) |
JP (1) | JP2000509049A (hu) |
AR (1) | AR006833A1 (hu) |
AU (1) | AU2698697A (hu) |
BR (1) | BR9709196A (hu) |
CA (1) | CA2252696A1 (hu) |
CZ (1) | CZ341098A3 (hu) |
HU (1) | HUP9901359A3 (hu) |
ID (1) | ID16660A (hu) |
IL (1) | IL126696A0 (hu) |
MA (1) | MA26426A1 (hu) |
NO (1) | NO984939L (hu) |
NZ (1) | NZ332476A (hu) |
PE (1) | PE64398A1 (hu) |
PL (1) | PL329530A1 (hu) |
TR (1) | TR199802160T2 (hu) |
WO (1) | WO1997041098A1 (hu) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4095804B2 (ja) | 2000-02-16 | 2008-06-04 | スミスクライン ビーチャム ピー エル シー | Ldl−pla2阻害剤としてのピリミジン−4−オン誘導体 |
DK1373230T3 (da) | 2001-03-28 | 2005-11-07 | Schering Corp | Enantiselektiv syntese af azetidinon mellemprodukter |
ATE345792T1 (de) * | 2001-05-25 | 2006-12-15 | Schering Corp | Verwendung von mit azetidinon substituierten derivaten bei der behandlung der alzheimer- krankheit |
EA200971050A1 (ru) | 2007-05-11 | 2010-06-30 | Томас Джефферсон Юниверсити | Способы лечения и предупреждения нейродегенеративных заболеваний и нарушений |
US8962633B2 (en) | 2007-05-11 | 2015-02-24 | Thomas Jefferson University | Methods of treatment and prevention of metabolic bone diseases and disorders |
EP2155225B1 (en) | 2007-05-11 | 2015-07-08 | The Trustees of the University of Pennsylvania | Methods of treatment of skin ulcers |
US20130252963A1 (en) | 2010-12-06 | 2013-09-26 | Yun Jin | Pyrimidinone compounds for use in the treatment of disease or conditions mediated by lp-pla2 |
US20130267544A1 (en) | 2010-12-17 | 2013-10-10 | Peter Adamson | Use of LP-PLA2 Inhibitors in the Treatment and Prevention of Eye Diseases |
US20140171431A1 (en) | 2011-06-27 | 2014-06-19 | Jianhua Shen | Azole heterocyclic compound, preparation method, pharmaceutical composition and use |
AU2012288865B2 (en) | 2011-07-27 | 2015-10-01 | Glaxo Group Limited | Bicyclic pyrimidone compounds |
EP2739627A4 (en) | 2011-07-27 | 2015-01-21 | Glaxo Group Ltd | 2,3-DIHYDROIMIDAZO [1,2-C] PYRIMIDIN-5 (1H) -ONE COMPOUNDS AND USE AS INHIBITORS OF LP-PLA2 |
JP2016505053A (ja) | 2013-01-25 | 2016-02-18 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | Lp‐PLA2の阻害剤としての二環式ピリミドン化合物 |
BR112015017759B1 (pt) | 2013-01-25 | 2022-05-24 | Glaxosmithkline Intellectual Property Development Limited | Compostos inibidores de fosfolipase a2 associada à lipoproteína (lp-pla2) à base de 2,3-dihidroimidazol[1,2-c]pirimidin5(1h)-ona, e composição farmacêutica compreendendo tais compostos |
AU2014210259B2 (en) | 2013-01-25 | 2016-11-03 | Glaxosmithkline Intellectual Property Development Limited | Compounds |
WO2016012916A1 (en) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
WO2016012917A1 (en) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
PE20230092A1 (es) | 2019-11-09 | 2023-01-16 | Shanghai Simr Biotechnology Co Ltd | Derivado triciclico de dihidroimidazopirimidona, metodo de preparacion del mismo, composicion farmaceuticas y uso del mismo |
CN115304620A (zh) | 2021-05-07 | 2022-11-08 | 上海赛默罗生物科技有限公司 | 嘧啶酮衍生物、其制备方法、药物组合物和用途 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4680391A (en) * | 1983-12-01 | 1987-07-14 | Merck & Co., Inc. | Substituted azetidinones as anti-inflammatory and antidegenerative agents |
IL89835A0 (en) * | 1988-04-11 | 1989-12-15 | Merck & Co Inc | Substituted azetidinones,their preparation and pharmaceutical compositions containing them |
IL99658A0 (en) * | 1990-10-15 | 1992-08-18 | Merck & Co Inc | Substituted azetidinones and pharmaceutical compositions containing them |
WO1993000332A1 (en) * | 1991-06-25 | 1993-01-07 | Merck & Co., Inc. | Substituted azetidinones as anti-inflammatory and antidegenerative agents |
ES2107548T3 (es) * | 1991-07-23 | 1997-12-01 | Schering Corp | Compuestos de beta-lactama sustituidos utiles como agentes hipocolesterolemicos y procedimientos para su preparacion. |
MY128261A (en) * | 1992-10-27 | 2007-01-31 | Merck Sharp & Dohme | New substituted azetidinones as anti-inflammatory and antidegenerative agents |
WO1994013636A1 (en) * | 1992-12-17 | 1994-06-23 | Merck & Co., Inc. | New substituted azetidinones as anti-inflammatory and antidegenerative agents |
DE69423436T2 (de) * | 1993-06-25 | 2000-09-07 | Smithkline Beecham P.L.C., Brentford | An lipoprotein gebundene phospholipase a2, inhibitoren davon und deren verwendung für diagnose und therapie |
ATE201905T1 (de) * | 1993-10-06 | 2001-06-15 | Icos Corp | Acethylhydrolase des plättchen aktivierenden faktors |
GB9421816D0 (en) * | 1994-10-29 | 1994-12-14 | Smithkline Beecham Plc | Novel compounds |
BR9510420A (pt) * | 1994-12-22 | 2004-04-20 | Smithkline Beecham Plc | Azetidin-2-onas substituìdas para o tratamento de aterosclerose |
AU5014496A (en) * | 1995-03-23 | 1996-10-08 | Japan Tobacco Inc. | Diphenylmethyl-azetidinone compounds and elastase inhibitor |
TR199701762T1 (xx) * | 1995-07-01 | 1998-05-21 | Smithkline Beecham P.L.C. | Damar t�kanmas� tedavisi i�in azetidinon t�revleri. |
WO1997021676A1 (en) * | 1995-12-08 | 1997-06-19 | Smithkline Beecham Plc | Azetidinone compounds for the treatment of atherosclerosis |
-
1997
- 1997-04-15 TR TR1998/02160T patent/TR199802160T2/xx unknown
- 1997-04-15 BR BR9709196A patent/BR9709196A/pt not_active Application Discontinuation
- 1997-04-15 HU HU9901359A patent/HUP9901359A3/hu unknown
- 1997-04-15 NZ NZ332476A patent/NZ332476A/en unknown
- 1997-04-15 CA CA002252696A patent/CA2252696A1/en not_active Abandoned
- 1997-04-15 WO PCT/EP1997/001898 patent/WO1997041098A1/en not_active Application Discontinuation
- 1997-04-15 JP JP9538507A patent/JP2000509049A/ja active Pending
- 1997-04-15 EP EP97920699A patent/EP0915843A1/en not_active Withdrawn
- 1997-04-15 IL IL12669697A patent/IL126696A0/xx unknown
- 1997-04-15 PL PL97329530A patent/PL329530A1/xx unknown
- 1997-04-15 CZ CZ983410A patent/CZ341098A3/cs unknown
- 1997-04-15 AU AU26986/97A patent/AU2698697A/en not_active Abandoned
- 1997-04-24 PE PE1997000311A patent/PE64398A1/es not_active Application Discontinuation
- 1997-04-24 AR ARP970101682A patent/AR006833A1/es unknown
- 1997-04-24 MA MA24565A patent/MA26426A1/fr unknown
- 1997-04-25 ID IDP971394A patent/ID16660A/id unknown
-
1998
- 1998-10-23 NO NO984939A patent/NO984939L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
TR199802160T2 (xx) | 1999-04-21 |
JP2000509049A (ja) | 2000-07-18 |
AU2698697A (en) | 1997-11-19 |
AR006833A1 (es) | 1999-09-29 |
PE64398A1 (es) | 1999-01-06 |
CZ341098A3 (cs) | 1999-03-17 |
IL126696A0 (en) | 1999-08-17 |
WO1997041098A1 (en) | 1997-11-06 |
MA26426A1 (fr) | 2004-12-20 |
EP0915843A1 (en) | 1999-05-19 |
ID16660A (id) | 1997-10-30 |
HUP9901359A3 (en) | 2000-03-28 |
NO984939D0 (no) | 1998-10-23 |
NO984939L (no) | 1998-12-23 |
CA2252696A1 (en) | 1997-11-06 |
HUP9901359A2 (hu) | 1999-08-30 |
PL329530A1 (en) | 1999-03-29 |
BR9709196A (pt) | 1999-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ332476A (en) | substituted 4-(carboxybenzylsulphinyl)-2-oxo-azetidine derivatives | |
KR100235806B1 (ko) | 저콜레스테롤혈증 치료제로서 유용한 황 치환된 아제티디논 화합물 | |
DE69222532T2 (de) | Substituierte beta-lactam-verbindungen als hypocholesterolemische mittel und verfahren zu deren herstellung | |
US6071899A (en) | Azetidinone derivatives for the treatment of atherosclerosis | |
JP2000505063A (ja) | アテローム性動脈硬化症の治療のためのアゼチジノン化合物 | |
PL122371B1 (en) | Process for manufacturing novel 2-penem-3-carboxylic compounds | |
IE49879B1 (en) | 2-penem compounds,a method for their preparation and pharmaceutical compositions comprising them | |
AU708032B2 (en) | Azetidinone derivatives for the treatment of atherosclerosis | |
WO1997021675A1 (en) | Monocyclic beta-lactame derivatives for treatment of atherosclerosis | |
JPH11500415A (ja) | アテローム性動脈硬化症治療用置換アゼチジン−2−オン | |
JPH05132458A (ja) | 抗炎症及び抗変性剤としての新規な置換アゼチジノン類 | |
JP2000509063A (ja) | アテローム性動脈硬化症の治療用アゼチジノン誘導体 | |
FI77661B (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara 2-oxiarylpenemer. | |
US4093626A (en) | β-Lactam antibiotics | |
JPS59108789A (ja) | ペネム化合物の製法 | |
WO2000023437A1 (fr) | Composes azotes hererocycliques condenses; procede de fabrication et agents les renfermant | |
JPH0819135B2 (ja) | 安定なオキサペネム‐3‐カルボン酸 | |
JPS6118760A (ja) | 抗細菌性7‐オキソ‐4‐チア‐1‐アザ ビシクロ〔3,2,0〕ヘプタ‐2‐エン誘導体 | |
MXPA98008924A (en) | Azetidinone derivatives for deeterosclero treatment | |
JPH06104672B2 (ja) | ペネム類の製造方法 | |
KR20000065040A (ko) | 아테롬성동맥경화증치료를위한아제티디논유도체 | |
JPH10306093A (ja) | エポキシ−アゼチジノン、その製造方法及びその使用 | |
JPH06128267A (ja) | ペネム誘導体およびその製造法 | |
JPH07509455A (ja) | セファロスポリンおよび1−カルバ−1−デチアセファロスポリン |